EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells

Matthieu Paiola, Daniel M Portnoy, Luke Yi Hao, Shoiab Bukhari, Robert J Winchester, Brian S Henick, Adam Mor, Yevgeniya Gartshteyn

Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010758

DOI: 10.1136/jitc-2024-010758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 21.03.2025. Verfasst von Matthieu Paiola und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Osteoarthritis, Memory T Cells, Arthritis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCRR NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T RM ) significantly eliminates cancer cells and is associated with irAE-related colitis and dermatitis. However, it remains unknown why the development of these irAEs is restricted to a subset of patients. We hypothesized that osteoarthritis (OA) associated tissue damage and chronic inflammation lead to the recruitment and differentiation of joint T RM cells, predisposing individuals to ICI-induced arthritis.

Methods

Using a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis.

Results

Our findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T RM cells expressing programmed cell death protein-1 (PD-1) were the predominant synovial T cells in OA joints. These cells were directly targeted by ICIs, resulting in an inflammatory immune response and the transition from OA to irAE-arthritis.

Conclusion

This study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T RM cells in OA joints, resulting in tissue inflammation and irAE-arthritis. This research could significantly enhance the management and treatment of patients with cancer receiving ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsOsteoarthritisMemory T CellsArthritisHumansMaleFemaleAgedMiddle AgedRisk Factors

Stichwörter der Autor:innen

AutoimmuneImmune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapyT cell

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
  • Department of Medicine, Division of Rheumatology, Columbia University Medical Center, New York, New York, USA.
  • Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Department of Medicine, Division of Rheumatology, Columbia University Irving Medical Center, New York, New York, USA.
  • Herbert Irvine Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.
  • Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA am5121@cumc.columbia.edu.

Förderung

  • NCRR NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • NIH
  • Roche

Zitieren

APA

Paiola, M., Portnoy, D. M., Hao, L. Y., Bukhari, S., Winchester, R. J., Henick, B. S., Mor, A., & Gartshteyn, Y. (2025). Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells. Journal for ImmunoTherapy of Cancer, 13(3), e010758. https://doi.org/10.1136/jitc-2024-010758

Vancouver

Paiola M, Portnoy DM, Hao LY, Bukhari S, Winchester RJ, Henick BS, et al. Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010758. doi:10.1136/jitc-2024-010758

BibTeX
@article{Paiola2025,
  author = {Paiola, Matthieu and Portnoy, Daniel M and Hao, Luke Yi and Bukhari, Shoiab and Winchester, Robert J and Henick, Brian S and Mor, Adam and Gartshteyn, Yevgeniya},
  title = {Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {e010758},
  doi = {10.1136/jitc-2024-010758}
}
Kostenlos starten →